A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home.

Authors: Hirata et al.

Expert Opin Drug Saf. 2022 Dec 28:1-8. Online ahead of print.

PMID: 36578197 | DOI: 10.1080/14740338.2023.2162038

Sign Up For An MSC Newsletter

Register to Watch the MSC Emerging Science Contest!

The MSC Emerging Science Contest for Young Investigators will take place on Wednesday, December 13, 2023, from 8-10 PM Eastern (US) time. We welcome those who wish to watch the event as an attendee. Register here to attend, and learn more about the contest here.



  • Content Types

  • Paper Categories

  • Paper Dates

Paper Categories

By Date